The Importance of Disease Burden after Induction and Prior to Transplantation in Patients with Acute Myeloid Leukaemia Receiving Allogeneic Transplantation

Claudia Nunez-Torron,Carlos Jimenez Chillon,Fernando Martin Moro,Alejandro Luna,Adolfo Saez,Kyra Velazquez-Kennedy,Juan Marquet Palomanes,Miguel Piris-Villaespesa,Valentin Garcia-Gutierrez,Anabelle Chinea,Gemma Moreno Jimenez,Javier Lopez Jimenez,Pilar Herrera

Blood（2021）

引用 0|浏览18

暂无评分

摘要

Introduction: Response to chemotherapy treatment both by cytology and by more sensitive techniques such as cytometry is one of the most influential parameters in the survival of patients with Acute Myeloid Leukaemia (AML). Patients with detectable minimal residual disease (MRD) or those with active disease (AD) after induction or prior to allogeneic transplantation (HCST) represent a high-risk group.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要